Evaluate the Long-term (3 Months) Efficacy of L-threo DOPS (DroxiDopa) on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With Multiple System Atrophy (MSA). Comparative Study Versus Placebo
Phase of Trial: Phase II/III
Latest Information Update: 09 Mar 2017
At a glance
- Drugs Droxidopa (Primary)
- Indications Neurodegenerative disorders
- Focus Therapeutic Use
- 05 Mar 2017 Planned End Date changed from 1 Feb 2017 to 1 Dec 2018.
- 05 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2018.
- 19 Jan 2016 Planned End Date changed from 1 Feb 2016 to 1 Feb 2017 as reported by ClinicalTrials.gov record.